Homocysteine and cardiovascular disease

Current Atherosclerosis Reports

Volumn 6, Issue 2, 2004, Pages 101-106

  Kalra, Dinesh K ^a  

^a Heart Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BEZAFIBRATE; BLOOD CLOTTING FACTOR 5; C REACTIVE PROTEIN; CHOLESTEROL; CYANOCOBALAMIN; DOPAMINE; FENOFIBRATE; FOLIC ACID; GEMFIBROZIL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; METHOTREXATE; NICOTINIC ACID; NITROUS OXIDE; PEROXYNITRITE; PLATELET DERIVED GROWTH FACTOR; PROTEIN C; PYRIDOXINE; RESIN; THEOPHYLLINE; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; VITAMIN B GROUP;

AMINO ACID BLOOD LEVEL; ATHEROSCLEROSIS; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DATA ANALYSIS; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; FRUIT; GENETIC VARIABILITY; HEART DISEASE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MEDICAL RESEARCH; MORTALITY; PATHOLOGY; POPULATION RESEARCH; RESTENOSIS; REVIEW; SCREENING TEST; THROMBOSIS; VASCULAR ENDOTHELIUM; VEGETABLE; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

EID: 3142768388     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-004-0097-3     Document Type: Review

References (21)

1. Malinow MR, Boston AG, Krauss RM, Homocyst(e)ine, diet, and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999,99:178-182.
2. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002,325:1202.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-1057.
4. Nygard O, Nordrehaug JE, Refsum H, et al.: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997, 337:230-236.
5. Anderson JL, Muhlestein JB, Horne BD, et al.: Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000, 102:1227-1232.
6. Hoogeveen EK, Kostense PJ, Eysink PE, et al.: Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med 2000, 160:2984-2990.
7. Stubbs PJ, Al Obaidi MK, Conroy RM, et al.: Effect of plasma homocysteine concentration on early and late events in patients wit acute coronary syndromes. Circulation 2000, 102:605-610.
8. Schnyder G, Roffi M, Pin R, et al.: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001, 345:1593-1600.
9. Graham IM, Daly LE, Refsum HM, et al.: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997,277:1775-1781.
10. Nishio E, Watanabe Y: Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br. J Pharmacol 1997, 122:269-274.
11. Dalton ML, Gadson PF Jr, Wrenn RW, Rosenquist TH: Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997, 11:703-711.
12. Woo KS, Sanderson JE, Sun YY, et al.: Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 2000, 101:E116.
13. Van den BM, Boers GH, Franken DG, et al.: Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995, 25:176-181.
14. Chambers JC, Ueland PM, Obeid OA, et al.: Improved vascular endothelial function after oral B vitamins: An effect mediated through concentrations of free plasma homocysteine. Circulation 2000, 102:2479-2483.
15. Stein JH, Bushara M, Bushara K, et al.: Smoking cessation, but not smoking reduction, reduces plasma homocysteine levels. Clin Cardiol 2002, 25:23-26.
16. Schnyder G, Roffi M, Flammer Y, et al.: Effect of homocysteine lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002, 288:973-979.
17. Zairis MN, Ambrose JA, Manousakis SJ, et al.: The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002, 40:1375-1382.
18. Schnyder G, Ruovinez G: Total plasma homocysteine and restenosis after percutaneous coronary angioplasty: current evidence. Ann Med 2003, 35:156-163.
19. Vasan RS, Beiser A, D'Agostino RB, et al.: Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003, 289:1251-1257.
20. Mangoni AA, Jackson SH: Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002, 112:556-565.
21. Carlsson CM, Stein JH, Clinical trials testing the homocysteine hypothesis. Ann Intern Med 2002, 137:295-296.